WO2002054073A3 - Latent human tuberculosis model, diagnostic antigens, and methods of use - Google Patents

Latent human tuberculosis model, diagnostic antigens, and methods of use Download PDF

Info

Publication number
WO2002054073A3
WO2002054073A3 PCT/US2002/000309 US0200309W WO02054073A3 WO 2002054073 A3 WO2002054073 A3 WO 2002054073A3 US 0200309 W US0200309 W US 0200309W WO 02054073 A3 WO02054073 A3 WO 02054073A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
human tuberculosis
diagnostic antigens
latent human
tuberculosis model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000309
Other languages
French (fr)
Other versions
WO2002054073A2 (en
Inventor
Frederick D Quinn
Kristin A Birkness
Manon Deslauriers
Peter King
David S Beall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Centers of Disease Control and Prevention CDC
Original Assignee
US Department of Health and Human Services
Centers of Disease Control and Prevention CDC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Centers of Disease Control and Prevention CDC filed Critical US Department of Health and Human Services
Priority to CA2433069A priority Critical patent/CA2433069C/en
Priority to US10/250,930 priority patent/US7105170B2/en
Priority to EP02704064A priority patent/EP1360498B1/en
Priority to AU2002237764A priority patent/AU2002237764B2/en
Priority to JP2002554720A priority patent/JP3944452B2/en
Priority to AT02704064T priority patent/ATE445839T1/en
Priority to DE60234015T priority patent/DE60234015D1/en
Publication of WO2002054073A2 publication Critical patent/WO2002054073A2/en
Anticipated expiration legal-status Critical
Publication of WO2002054073A3 publication Critical patent/WO2002054073A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)

Abstract

Provided herein is an in vitro granuloma model and methods of its use. Methods of detecting and/or diagnosing latent tuberculosis in a subject are also provided, as are latency-specific antigens (and antibodies thereto), such as α-crystallin, and methods of identifying and using such molecules. Also provided are immunostimulatory compositions, for instance for use in eliciting an immune response in a subject, such as an immune response to a latent tuberculosis infection. Kits for carrying out the provided methods are also described.
PCT/US2002/000309 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use Ceased WO2002054073A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2433069A CA2433069C (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use
US10/250,930 US7105170B2 (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use
EP02704064A EP1360498B1 (en) 2001-01-08 2002-01-07 Latent human tuberculosis diagnostic antigen and method of use
AU2002237764A AU2002237764B2 (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use
JP2002554720A JP3944452B2 (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigen, and method of use
AT02704064T ATE445839T1 (en) 2001-01-08 2002-01-07 LATENT TUBERCULOSIS DIAGNOSTIC ANTIGEN AND METHOD OF USE
DE60234015T DE60234015D1 (en) 2001-01-08 2002-01-07 LATENT TUBERCULOSIS DIAGNOSTIC ANTIGEN AND USE METHOD

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26034801P 2001-01-08 2001-01-08
US60/260,348 2001-01-08
US31123501P 2001-08-09 2001-08-09
US60/311,235 2001-08-09

Publications (2)

Publication Number Publication Date
WO2002054073A2 WO2002054073A2 (en) 2002-07-11
WO2002054073A3 true WO2002054073A3 (en) 2003-08-28

Family

ID=26947939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000309 Ceased WO2002054073A2 (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use

Country Status (8)

Country Link
US (1) US7105170B2 (en)
EP (1) EP1360498B1 (en)
JP (1) JP3944452B2 (en)
AT (1) ATE445839T1 (en)
AU (1) AU2002237764B2 (en)
CA (2) CA2433069C (en)
DE (1) DE60234015D1 (en)
WO (1) WO2002054073A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
ES2231037B1 (en) * 2003-10-31 2005-12-16 Archivel Technologies, Sl USEFUL IMMUNOTHERAPIC AGENT FOR THE COMBINED TREATMENT OF TUBERCULOSIS IN ASSOCIATION WITH OTHER PHARMACOS.
FR2872579B1 (en) * 2004-06-30 2006-11-24 Pasteur Institut DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA
CA2603356A1 (en) * 2005-03-31 2006-10-05 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
US8603751B2 (en) 2006-03-02 2013-12-10 The Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
US8012492B2 (en) * 2007-04-30 2011-09-06 University Of Central Florida Research Foundation, Inc. In vitro model of latent mycobacterial infection
US8058022B2 (en) 2009-07-27 2011-11-15 Indian Institute Of Science Diagnosis and monitoring of mycobacterium tuberculosis infection
WO2013112103A1 (en) * 2012-01-27 2013-08-01 Peas Institut Ab Method of detecting tuberculosis
CN110118871A (en) * 2012-12-28 2019-08-13 塞尔雷斯蒂斯有限公司 Cell-mediated immune response test
KR101552610B1 (en) 2013-09-24 2015-09-18 연세대학교 산학협력단 Animal model for the study of granuloma and method for producing the same
WO2016011280A1 (en) * 2014-07-16 2016-01-21 Tangen Biosciences, Inc. Isothermal methods for amplifying nucleic acid samples
US11559801B2 (en) 2014-11-03 2023-01-24 Tangen Biosciences, Inc. Apparatus and method for cell, spore, or virus capture and disruption
CN109030825A (en) * 2017-06-12 2018-12-18 广东体必康生物科技有限公司 Albumen Rv2031c for the infection of specific detection mycobacterium tuberculosis
RU2702609C1 (en) * 2018-08-06 2019-10-08 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Method for simulating tuberculosis infection in vitro
US12564179B2 (en) * 2019-06-28 2026-03-03 United States Government As Represented By The Department Of Veterans Affairs Methods of producing granulomas and animal models of sarcoidosis
CN115598041B (en) * 2021-07-07 2025-08-19 中国科学院微生物研究所 Tuberculosis differential diagnosis cytokine and application thereof in tuberculosis infection risk assessment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026007A1 (en) * 1996-01-17 1997-07-24 Trustees Of Boston University Mycobacterium antigens and methods for their detection
WO1998029132A1 (en) * 1996-12-31 1998-07-09 New York University Early detection of mycobacterial disease
WO1999002670A1 (en) * 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2249208A1 (en) * 1996-03-27 1997-10-02 The Johns-Hopkins University Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
US5700925A (en) 1996-03-27 1997-12-23 The Johns Hopkins University DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis
US5824546A (en) 1996-03-27 1998-10-20 The Johns Hopkins University Regulation of a sigma factor from Mycobacterium tuberculosis
EP1029053A1 (en) * 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026007A1 (en) * 1996-01-17 1997-07-24 Trustees Of Boston University Mycobacterium antigens and methods for their detection
WO1998029132A1 (en) * 1996-12-31 1998-07-09 New York University Early detection of mycobacterial disease
WO1999002670A1 (en) * 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM ADAM F ET AL: "Mycobacterial stationary phase induced low oxygen tension: Cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog.", JOURNAL OF BACTERIOLOGY, vol. 180, no. 4, February 1998 (1998-02-01), pages 801 - 808, XP002217752, ISSN: 0021-9193 *
WAYNE LAWRENCE G ET AL: "An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.", INFECTION AND IMMUNITY, vol. 64, no. 6, 1996, pages 2062 - 2069, XP002240188, ISSN: 0019-9567 *
WILKINSON R J ET AL: "Human T- and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 48, no. 4, October 1998 (1998-10-01), pages 403 - 409, XP002217751, ISSN: 0300-9475 *
YUAN ET AL: "Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 178, no. 15, 1 August 1996 (1996-08-01), pages 4484 - 4492, XP002086106, ISSN: 0021-9193 *

Also Published As

Publication number Publication date
AU2002237764B2 (en) 2007-08-23
JP2005506512A (en) 2005-03-03
ATE445839T1 (en) 2009-10-15
CA2433069C (en) 2010-03-30
EP1360498B1 (en) 2009-10-14
US20040146933A1 (en) 2004-07-29
CA2689741C (en) 2013-10-01
CA2433069A1 (en) 2002-07-11
US7105170B2 (en) 2006-09-12
EP1360498A2 (en) 2003-11-12
CA2689741A1 (en) 2002-07-11
DE60234015D1 (en) 2009-11-26
WO2002054073A2 (en) 2002-07-11
JP3944452B2 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
ATE445839T1 (en) LATENT TUBERCULOSIS DIAGNOSTIC ANTIGEN AND METHOD OF USE
HUP0103085A1 (en) Formulations an processes for inducing an immune response to polysaccharide
BR0009166A (en) Vaccine
PT1162997E (en) STAPHYLOCOCCUS ANTIGENIC AND RESPECTIVE VACCINE
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2001098460A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
WO2023172741A3 (en) A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine comprising b- and t-cell antigens, immunogenic composition, and uses thereof
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
WO2004032599A3 (en) Novel immunogenic proteins of leptospira
JP2004503217A5 (en)
WO2000044392A3 (en) Identification of specific differentially expressed mycobacterial antigens
WO2003080839A3 (en) Antigen fragments for the diagnosis of toxoplasma gondii
WO2001040472A3 (en) Streptococcus pneumoniae antigens
DK0809653T3 (en) Helicobacter pylori antigen
WO2003076570A3 (en) Antigens and their use as diagnostics and vaccines against species of plasmodium
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
AU2003288711A1 (en) Polypeptides for the diagnosis and therapy of leishmaniasis
ZA98587B (en) A novel antigen from P. aeruginosa, and its use in medicine.
WO1999061909A3 (en) Methods and compositions for the detection of human herpesvirus
DE60021409D1 (en) NEUROKININ B PRELIMINARY FROM HUMAN PLAZENTA
AU2002359984A1 (en) Salmonella antigen formulation and antibody test kit and subunit vaccine using the same
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
ATE396402T1 (en) IN VITRO DIAGNOSTIC TEST OF ENTEROVIRUS INFECTIONS
JP2004514412A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2433069

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002237764

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002554720

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002704064

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002704064

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10250930

Country of ref document: US